Mutlukan, Erkan – Trademark Portfolio

Entity Type: 01

Mutlukan, Erkan holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include GLARESCOPE GLAREOSCOPE EYETECH-SYSTEMS. The owner is based in Springfield, MA.

159 Sumner Ave. Apt 8

Springfield, MA 01108

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Mutlukan, Erkan's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Mutlukan, Erkan have?

Mutlukan, Erkan has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.

What trademark classes does Mutlukan, Erkan file in?

Mutlukan, Erkan files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.

What are Mutlukan, Erkan's most well-known trademarks?

Mutlukan, Erkan's registered trademark portfolio includes well-known marks such as GLARESCOPE GLAREOSCOPE EYETECH-SYSTEMS. These are among 1 currently registered trademark in the portfolio.

What is Mutlukan, Erkan's trademark registration success rate?

Mutlukan, Erkan has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.